Index

Note: Page numbers with italicized f’s and t’s refer to figures and tables, respectively.

abdominal colectomy, 192
abdominal CT scanning, use of, in ED, 253
aberrant crypt foci (ACF), 70
acute gastroenteritis, and IBD, 15
adalimumab (ADA), 109, 110
and mucosal healing, 204
in pregnancy, 134
adenoma-like mass (ALM), 59
adherence
guidelines for, 249
no-blame approach for, 249
patients’ beliefs about medicines and, 248–9
perceptual barriers, 248
PPA for improving of, 248
practical barriers, 248
alert bracelet, 21
allopurinol, 153
use of, in shunters, 87–8
aloe vera gel, use of, 165
American Gastroenterological Association, 244
5-aminosalicylic acid (5-ASA), 65, 73
chemopreventive effect of, 69–70, 75
evidence for, 70–71, 71f
dosing of, optimal, 66–7, 66f
efficacy and safety of, for UC, 65–6, 73
formulations of, action mechanism and pharmacology of, 65
mesalamine, newer formulations of, 65
newer delayed-release formulations, efficacy of, 67
oral formulations of, 65
adverse effects of, 66
postoperative maintenance, role in, 74
use of, in Crohn’s disease for induction of remission, 73–4
for maintenance of remission, 74
anal abscesses, 183
Andrographis paniculata, 165–6
anemia, in IBD, 237–8
anemia of chronic disease, 237–8
definition of, 237
diagnostic steps for, 238
erthropoietin treatment for, 239–40
intravenous iron supplementation in, 239, 239f
iron deficiency as cause of, 237
prevalence of, 237
screening for, 238
severe, 237
therapy for, 238–9
types of, 237–8
antibody-dependent cell-mediated toxicity (ADCC), 109
antibody to bacterial flagellin (CBir1), 48–9
anti-integrin therapy, 142. See also natalizumab
antimalarial agents, 20
antineutrophil cytoplasmic antibody with perinuclear staining (pANCA), 48, 49
anti-Saccharomyces cerevisiae antibody (ASCA), 48–9
anti-TNF (antitumor necrosis factor) therapy, 80. See also antitumor necrosis factor (anti-TNF) agents
cancer risk after, 136
for Crohn’s disease, 111, 113, 124
discontinuation of practical considerations in, 145–6
reasons for, 144–5
studies on, 145
failure/loss of response to, 124–7
concomitant immunomodulator therapy use in, 125
cancer risk after, 136
earlier use in disease course in, 124–5
primary nonresponse in, 125–6
secondary loss of response in, 126, 127f
switching strategy in, 126

© 2011 Blackwell Publishing Ltd. Published 2011 by Blackwell Publishing Ltd.
Index

anti-TNF (antitumor necrosis factor) therapy (Continued) and HBV infection, 23–4 HBV serology before, 16–17 and HCV infection, 23–4 malignant disease, development of lymphoma in IBD, 137 in RCTs of anti-TNF therapy for other disease, 137 in RCTs of anti-TNF therapy in IBD, 136–7 in patients with previous malignancy, 137–8 risk of infections with, 16 screening for, 16 side effects of, 141–2 communication of, 142 and TB infection, 16, 20–21 use of, in pregnancy, 133–5 antitumor necrosis factor (anti-TNF) agents, 109, 113, 124, 140 adalimumab clinical efficacy of, 111 structure of, 109, 110f certolizumab pegol clinical efficacy of, 111 structure of, 109, 110f clinical efficacy of, 111 and concomitant immunomodulator therapy, 113. See also combination therapy etanercept, 109, 110f golimumab, 109, 110f immunogenicity of, 110–11 infliximab half-life of, 110 structure of, 109, 110f perioperative use of, and postoperative complications, 186, 188r–9t in Crohn’s disease, 186–7, 188r–9t in ulcerative colitis, 187, 189 pharmacokinetic properties of, 109–10, 110f structure and function of, 109, 110f apathous ulcers, 131 AprisoTM/Salofalk, 65, 67 arachidonic acid, 69 Artemisia absinthium, 165 aryl hydrocarbon receptor (AhR) agonists, 5 Asacol® HD, 67 ASCEND trials, 66 aspirin, chemopreventive effect of, 71 ASTIC trial, 161 autofluorescence imaging (AFI), 59 automatic tube current modulation (ATCM), 53 axial arthropathies, 129 azathioprine (AZA), 16, 85, 94, 172. See also thiopurines as risk factor for cervical cancer, 95 role in UV-induced skin carcinogenesis, 91 azithromycin, 20 bacterial infections, 15 balsalazide, 65 basal cell carcinomas (BCC), 89 bifidobacteria species, 34 biologics, in UC with immunomodulators, 121 initiation of hospitalized patients, 121 infliximab for hospitalized severe UC patient, 121 outpatient setting, 120–21 selection of, 121–2 at time of surgery perioperative use, 122 postoperative use, 122 biologic therapies, 124, 140 during breastfeeding, 134 for extraintestinal manifestations, of IBD, 129–31 use of, in pregnancy, 133 adalimumab, 134 certolizumab, 134 infliximab, 133–4 natalizumab, 134 and newborn management, 134–5 third trimester, modification in, 134 biomarkers classical, 47 definition of, 47 emerging serological, 48r–9, 48tr fecal, 48, 48tr strengths and weaknesses of, of gut inflammation, 48t bismuth enemas, 197 bone marrow suppression, 28 Boswellia serrata, 165 breastfeeding, 212, 233 anti-TNF treatment in, 134 effect of nursing on IBD, 212–13 herbal supplements in, 214 issues in, 214 medication safety during infliximab, 213 mesalamine, 213 other drugs, 213–14 prednisone, 213 thiopurines, 213 British National Formulary, 154 British Society of Gastroenterology (BSG), 57 colitis surveillance algorithm, 58f British Society of Rheumatology (BSR), 138 budesonide enemas, 197 calcineurin inhibitors, 90, 102 comparative toxicity of, 104 cyclosporine in UC, 102 pharmacology of, 103 side effects of, 103 tacrolimus in UC, 102–3 timing of intervention of, 103–4 use of, 102 calprotectin, fecal, 48, 196 cardiopulmonary exercise testing, use of, 172 CD activity index (CDAI), 203 CD endoscopic index of severity (CDEIS), 203, 205f C. difficile infection (CDI), in IBD patients, 30 corticosteroids use in, 32 diagnosis of, 31 immunosuppresion as risk factor for, 31 presentation and assessment of, 31 prevalence and impact of, 30–31 prevention of, 32 prognosis for, 31 recurrence of, 32 risk factors for, 31 treatment of, 31–32 celecoxib, 71 Center for Disease Control and Prevention (CDC), 41 Centers of Disease Control Web site, 20 ceramide, 69
certolizumab pegol (CERTO), 109, 110
in pregnancy, 134

cervical cancer
incidence of, 94
minimizing risks of, 96
prognosis of, in thiopurine-treated IBD, 95
risk of, in thiopurine-treated IBD, 95

cervical cancer screening programs, 96

chest X-ray, in ED, 253

clofibrate, 207

ciprofloxacin, 20, 197

classical biomarkers, 47, 48

Clostridium difficile, 30
infection, 15

CMV DNA testing, 28

colicine, 154
coleectomy, 104

colorectal cancer (CRC), in IBD patients, 57, 69, 222
epidemiology of, 222
estimation of risk of controversies on, 222–3
population-based studies on, 223, 224
further research on, need of, 225
risk factors for, 222
in UC
5-ASAs for, use of, 69–71, 75
combination therapy, 113, 121
COMMIT study of, 114
efficacy of, 113–14
patient characteristics and use of, 115
SONIC trial, data from, 114, 118
toxicity of, 114
infection, 114–15
lymphoma, 115

complementary and alternative medicine (CAM), 164
physicians responses to patients on, 166
types of, 165
use of, by IBD patients, 164
aloe vera gel, 165
Andrographis paniculata, 166
Boswellia serrata, 165
curcumin, 166
evidence for, 164–6
rationale for, 164

corticosteroid therapy, risk of infections with, 16
cosmesis, 178–9
cotrimoxazole, 103
cow’s milk, exclusion of, 231
C-reactive protein (CRP), 47, 48, 146
Crohn’s and Colitis Foundation of America’s Web site, 21–2
Crohn’s Disease Activity Index (CDAI), 74
Crohn’s disease (CD)
age of diagnosis of, 9, 9t
anti-TNF therapy for. See anti-TNF (antitumor necrosis factor) therapy
discontinuation of, 144–6
behavior, 9
depression in, 216
down-staging of, 171
early aggressive therapy for, 117–19.
See also complicated disease
enteral feeds in, 229, 231
helminthic therapy, 39
laparoscopy for, 178–9
limited ileocecal, 175
medical treatment of, 175
recurrent disease after surgery, 176
surgical treatment of, 176
locations of, in different countries, 9, 9t
male predominance of, 9
mucosal healing in, 203–4
NOD2 mutations in, 8, 8f
noninflammatory strictures in, 220
perianal manifestations of. See perianal CD
perioperative use of anti-TNF, and postoperative complications in, 186–7, 188–9t
radiation exposure in, 51. See also radiation exposure, in IBD
stem cell transplantation for, 159–62
Crossing the Quality Chasm, 243
curcumin, 165
cyclooxygenase-2 (COX-2), 69
cyclophilins, 24
cyclosporine, 24, 102. See also calcineurin inhibitors
CYP1A2, 151
CYP3A4, 154
cytomegalovirus (CMV) infection, 27
active, 27
diagnosis of, 27–8, 28t
latent, 27
steroid-refractory cases, antiviral therapy in, 28
treatment of, 28
7-dehydrocholesterol, 207
de novo CD
development of, 193–4
predictors of, 194
depression, in IBD, 216. See also stress
diet advice in IBD, 231
case study on, in CD, 229, 230f
enteral feeds, in CD, 229, 231
future work on, need for, 231
and IBD, relationship between, 229–30
intervention studies on dietary modification, 231
enteral nutrition, 230–31
malnutrition in IBD, 231
and risk of IBD, 233
role, in IBD causation, 229
digital rectal examination, 253
Doppler cardiac output monitoring, 173
drug interactions, 151, 152–3t
antibiotics, 151
and probiotics, 151
anti-TNF therapy
thiopurines, 154
cigarette smoke and, 154
corticosteroids
COX-2 inhibitors with, 153
and NSAIDs, 153
Index

- drug interactions (Continued)
  - cyclosporine
  - colchicine and, 154
  - corticosteroids/thiopurines/methotrexate and, 154
  - statins with, 154
  - methotrexate
    - aspirin/NSAIDs with, 153–4
    - and ciprofloxacin, 154
    - trimethoprim and, 154
  - sulfasalazine 5-ASAs and azathioprine/mercaptopurine, 151
  - thiopurines
    - allopurinol with, 153
    - and methotrexate, 153
  - warfarin and IBD drugs, 154
  - dysplasia-associated lesions/masses (DALMs), 59
  - dysplasia, in UC patients, 9

- educational process, for radiation protection, 54

- emergency department (ED) visits, by IBD patients, 251
  - analgesic for use in, selection of, 253
  - approach in, 251–2
  - blood and stool tests, 253
  - history examination, 252
  - imaging in ED, 253
  - physical examination, 252–3
  - treatment, 253
  - complications of IBD for, 252
  - corticosteroid therapy initiation in, 253
  - fluid depletion and, 253
  - improvement in care in
    - ED staff training for, 254
    - IBD team for, 254
  - patients education and support for, 254
  - non-IBD related attendances, 253–4
  - with perianal disease, 253
  - rate of, 251
  - reasons for, 251
  - VTE prophylaxis in, 253–4
  - emulsifiers, 231
  - endemic infections, 19–20
  - endoscopic ultrasound (EUS), for perianal disease, 183
  - enhanced recovery after surgery (ERAS), 173
  - enteral nutrition (EN)
    - for CD, 234–5
    - role in maintaining remission in CD, 235
  - environmental factors, role in IBD development, 9
  - enzyme-linked immunosorbent assays (ELISA) tests
    - CDI diagnosis by, 31
  - epigenetic regulation, in IBD, 4
  - environmental factors influence on, 5
  - limitations of current studies of, 5
  - episcleritis, 131
  - Epstein–Barr Virus (EBV), 141
  - ergocalciferol, 207
  - erythema nodosum, 130
  - erythrocyte sedimentation rate (ESR), 47, 48

- Escherichia coli Nissle, 35

- etanercept, 109, 110

- European Association for the Study of the Liver (EASL), 24, 157

- European Council Euratom directive of 1997, 54

- European Crohn's and Colitis Organization (ECCO), 24, 41, 121, 161

- European Group for Blood and Marrow Transplantation (EBMT), 161

- exclusive enteral nutrition (EEN)
  - use of, 230–31

- extended spectrum β-lactamase resistant bacteria (ESBL), 199

- extraintestinal manifestations (EIMs)
  - of IBD, 9, 129
  - biologic agents for, 130
  - hepatobiliary complications, 131
  - musculoskeletal, 129
  - ocular complications, 131
  - oral manifestations, 131
  - pathogenesis of, 129
  - skin manifestations
    - erythema nodosum, 130
    - pyoderma gangrenosum, 130
    - Sweet's syndrome, 131

- fecal calprotectin, 146

- fecal coliform sensitivity testing, 198

- fecal S100A12, 48

- fenugreek (Trigonella foenum-graecum), 214

- ferric carboxymaltose, 239, 239

- fibrostenotic disease, 175

- fissures, 182–3

- fistulizing disease, 183

- flexible pouchoscopy, 196

- foscarnet, 28

- fructooligosaccharides (FOS), 35–6

- ganciclovir, 28

- Ganzoni's formula, for total iron deficit (ID), 238

- gene deserts, 4

- genetic variation, in IBD, 4

- gene transcription regulation, by epigenetic mechanisms, 3–4

- genome, human, 3

- genome-wide association scans (GWAS) studies, 3–4

- genotypic differences, between Western and Asian IBD, 7–9

- GETAID “bridge” study, 145

- glucocorticosteroids. See steroids

- golimumab, 109, 110

- growth failure, in children with IBD, 234

- hand-washing, for prevention of CDI, 32

- Harvey–Bradshaw index (HBI), 203

- healthcare quality. See also quality of care
  - definition of, 243
  - helminthic therapy, 38

- clinical trials on, for treating IBD, 39

- immune-modulatory effects of, 39–40, 39

- for other immunological disorders, 39

- rationale for use of, in IBD treatment, 38–9

- helminths, 38

- hematopoietic stem cell transplantation (HSCT), in Crohn's disease, 159

- allogenic, 161

- ASTIC trial on, 161

- autologous, 161

- rationale for, 159–60

- safety of, 161

- studies on, 160–61, 160

- hepatic fibrosis, 99
hepatitis B vaccination, 43
hepatitis B virus (HBV), 16
IBD treatment in patients with, 24
infection with, in IBD patients, 23
screening for, 24
hepatitis C virus (HCV), 17
IBD treatment in patients with, 24–5
infection with, in IBD patients, 23
hepatobiliary complications, of IBD, 131
hepatosplenic T-cell lymphomas (HSTCLs), 115, 137, 142, 154
herpes zoster virus, 17–18
Ho index, 104
HPV vaccine, 43
human papilloma virus (HPV), 43
and cervical cancer, 94. See also cervical cancer
25-hydroxyvitamin D (25OHD), 207
hyoscine-N-butylbromide, 58
I2 antibody, 48–9
IBD hygiene hypothesis, 38
animal studies and, 39
epidemiological studies and, 39
population genetic analysis and, 39
ileal pouch-anal anastomosis (IPAA), 192
Crohn's disease in, diagnosis of, 193
after IPAA, 193–4
crohn's colitis diagnosed at colectomy, 193
preoperative colonic Crohn's disease, 193
laparoscopic surgery for, 179–80
outcome of, in IC patients, 193
ileocolic resection, 178–9
Image Gently, 54
imaging modalities, for IBD advantages and disadvantages of, 54
radiation exposures associated with, 52
imaging, preoperative, role of, 172
immunocompromised status, 42
immunomodulators, 140. See also azathioprine (AZA);
6-mercaptopurine (6MP);
methotrexate (MTX)
side effects of, 140–41, 141
with steroid therapy, 80
indeterminate colitis (IC), 192–3
infection risk, IBD therapies and, 16–18
hepatitis B, 16–17
herpes viruses, infection with, 17–18
tuberculosis, 16
Inflammatory Bowel Disease Standards Group, 245
infliximab (IFX), 109, 110, 113
breastfeeding and use of, 213
erythema nodosum and, 130
in IBD-associated joint disease, 129
and mucosal healing, 204
nonresponse to, 125
perioperative use, 122
and postoperative complications, 188–9
postoperative use, 122
in pregnancy, 133–4
in pyoderma gangrenosum, 130
in Sweet's syndrome, 131
in IBD patients, 178–9
for ileal pouch-anal anastomosis, 179–80
subtotal colectomy and panproctocolectomy, 179
for ulcerative colitis, 179
liver biopsies, 24, 25
leukopenia, 87, 151
Lialda®/Mezavant, 65, 67
linoleic acid, 230, 233
liver function tests, 99
liver inflammation, 24
live vaccines, avoidance of, 20
low-dose CT, 53
low-grade dysplasia (LGD), diagnosis of, 59
idiopathic pulmonary fibrosis, combination therapy and, 115
macrocystis, 100
magnetic resonance imaging (MRI), 53–4, 54
malaria, 20
malignant disease, anti-TNF therapy and, 136–8
meningococcal disease, 19–20
meningococcal vaccination, 43
6-mercaptopurine (6-MP), 16, 85, 94.
See also thiopurines
mesalamine, 65. See also 5-aminosalicyclic acid (5-ASA)
use of, during breastfeeding, 213
mesenchymal stem cells (MSC), 159, 161
for transplantation, 161–2
methotrexate (MTX), 24, 98
adverse effects of, 99–100, 141
as alternative to thiopurines, 99
in IBD, efficacy of, 99
optimal use of, in IBD patients, 100r
pharmacology of, 98–9
pregnancy outcomes with, adverse, 100
6-methylmercaptopurine (6-MMP), 85–6
methylprednisolone, 79. See also steroids
metronidazole, 197
for CDI treatment, 31
microbiota, in IBD, 34–5
micronutrient deficiency, in IBD, 231
microparticles, in diet, 231
Mina, 4
mismatch repair (MMR) system, 91
MMR-deficient cells, 92
mood/anxiety disorders, treatment of, 217
mucosal healing
in Crohn's disease, 203–4
defined, 204
in ulcerative colitis, 204–5
musculoskeletal EIMs, 129
Mycobacterium tuberculosis, 16
narrow-band imaging (NBI), 59
natalizumab, 126
use in pregnancy, 134
National Institutes of Health (NIH), 47
natural orifice transluminal endoscopic surgery (NOTES), 173
Necator americanus, 39
negligence, 259
Neisseria meningitidis, 20
newborns, anti-TNF levels in, 134–5
NICE (National Institute of Health and Clinical Excellence), 249
NOD2 gene, 8
noise reduction filters, 53
nonadherence, to drug therapy, 247
intentional, 248
myths of, 247–8
unintentional, 248
non-Hodgkins lymphoma (NHL) in IBD, risk of, 154
nonmelanoma skin cancer (NMSC), 89
NSAIDs, chemopreventive effect of, 71
nuclear factor kappa B (NFκB, 69
nucleoside analogue (NA) prophylaxis, 24
ocular complications, of IBD, 131
ostalazine, 65
oncogenic viruses, 91
organ transplant recipients, 89
OTIS (Organization for Teratology Information Specialists), 134
outcome measures, in IBD care, 244, 245
outer membrane porin C (OmpC), 48–9
pancolonic dye-spray, 59
panproctocolectomy, laparoscopic, 179
parasite infections, 15
parenteral nutrition (PN), for CD, 234
pay-for-performance (P4P) program, 244
pelvic MRI, for perianal disease, 183
Perfotasa®, 74
perceptions and practicalities approach (PPA), 247–8
perianal CD, 182
biologic therapy for, 184
diagnostic modalities for evaluation of, 183
fissures in, 182–3
fistulizing disease, 183
perianal abscesses in, 183
skin tags/hemorrhoids in, 182
strictures in, 182
treatment of, 183–4
perioperative optimization, of IBD surgery patients, 171
operative care, 172–3
postoperative care, 173
preoperative care, 171–2
peripheral arthropathy, 129
peroxisome proliferation activated receptor (PPAR-γ), 65, 70
phenotypes, IBD, 9
photoprotection, 92
Plasmodium falciparum, 20
platelets, 47, 48r
pneumococcal vaccination, 43
postinflammatory polyps, 59–60
posttransplant lymphoproliferative disorder (PTLD), 141
pouchitis, 196
antibiotics in, use of, 198–9
diagnosis of, 196–7
initial onset of, prevention of, 198
prebiotics and synbiotics use in, 35
prevalence of, 196
risk factors for, 196
treatment of, 197–8, 197f
acute pouchitis, 197
maintenance treatment, 198
prebiotics, 35. See also synbiotics
prednisolone, 79. See also steroids
prednisone, 79. See also steroids
pregnancy, with IBD, biologics in, 133–5
primary nonresponse, to anti-TNF therapy, 125
management in, 125–6
primary sclerosing cholangitis (PSC), in IBD patients, 156–7
chemoprotection against CRC, by UDCA, 157
colorectal cancer in, risk of, 156–7
UDCA treatment in, 157, 157f
primum non nocere, principle of, 138
probiotics, 35
probiotic therapy, in pouchitis, 198
process measures, in IBD care, 244, 245r
proctocolectomy, 156
progressive multifocal leukoencephalopathy (PML), 142
proton pump inhibitor use, 153
PTCH gene in BCCs, 92
pyoderma gangrenosum, 130
quality of care, 243, 258
for IBD, 244
IBD standards for, 244–5
future perspective on, 245–6
measures of outcomes, 244
process, 244
structure, 244
medicolegal pitfalls in failure to address medical errors, 259
failure to document, 258–9
negligence, 259
terminating care improperly, 259
Quality of Care Initiative, by Crohn's and Colitis Foundation of America, 244–5

radiation diary, 54

radiation exposure, in IBD, 51–2

CT and, 52–3

imaging procedures and, 52t, 54t

minimization of in CT, 53

imaging strategies for, 53–4

improving referral practices for, 54–5

reactive oxygen species (ROS), 70

refeeding syndrome, 234

restorative proctocolectomy (RPC), 196

rotavirus vaccine, live, for infants, 135

sacroiliitis, 129

Salmonella typhi, 19

Sandborn's 18-point pouch disease activity index (PDAI), 196

scleritis, 131

scopolamine, 58

SedaCrohn®, 166

sequential antibody testing, 49

serological biomarkers, 48–9

single incision laparoscopic surgery (SILS), 173

single nucleotide polymorphisms (SNPs), 3

6-mercaptopurine (6-MP), 16, 85

skin cancer

in IBD patients, 89–90

molecular mechanisms of, 90–91

risk factors for, 89

thiopurines use and, 90

strategies for reducing of clinical surveillance, 92

photoprotection, 92

risk assessment, 92

self-skin examination, 92

thiopurine withdrawal, 92

in transplant patients, 90

skin cancer surveillance clinics, 92

skin examination, 92

skin manifestations, in IBD patients, 130–31

small bowel capsule endoscopy, 146

small bowel MRI, 146

smoking cessation, CD and, 154

sodium ferric gluconate complex, 239

solar ultraviolet A (UVA) radiation, 89

squamous cell carcinomas (SCC), 89

statins, 154

stem cells, 159

steroids

adverse effects of, 80

and anti-TNF therapies, 80

benefits of, 79

dependence, 80

immunomodulators use with, 80

for inflammatory disorders, 79

limitations of therapeutic effects of, 79–80

in treatment of Crohn’s disease, 81

St. John’s wort, 214

stool culture, for CDI diagnosis, 31

stress, 215

depressive symptoms and CD, 215–16

gut inflammation by, increase in, 215

in IBD patients, 215–16

impact on management of IBD, 216–17

individual differences in vulnerability to, 216

psychological, and UC, 215–16

Th17 pathway, 8

titanium oxide, 231

to Err is Human, report by IOM, 243

Toxoplasma gondii, 16

traditional acupuncture and moxibustion (TAM), 165–6

transition, from pediatric to adult care, 255

barriers to, 255–6

parents role in, 256

process of, timeline for, 256–7

ages 11–13, 256

ages 14–16, 256

ages 17–19, 256–7

ages 20–23, 256–7

Web sites for assistance on, 257

travelers’ diarrhea, 20

talcum powder, 211

treatment of IBD, 196

Th-1 cytokines, 23

Th-2 cytokines, 23

6-thioguanine nucleotides (6-TGN), 85

6-thioguanine (6-TG), 89, 94

thiopurine methyltransferase (TPMT), 85, 151

thiopurines, 24, 89, 94

cervical cancer and use of, 95, 96t

goal in treatment with, 85

metabolism, 85–6, 86f

metabolite measurements, indications for, 86–8, 86t

nonadherence, 86–7

thiopurine refractory, 87

thiopurine resistant, 87

underdosing, 87

metabolite monitoring, role of, 85–6

mutagenicity

UV-dependent, 91

UV-independent, 91–2

role in carcinogenesis, 94–5

side effects of, 140–41, 141t

communication of, 142

and skin cancer, in IBD patients, 89–90. See also skin cancer

pathogenesis of, 90–91

use in transplant patients, 90

use of, in colon cancer, 71

UVA radiation and, 89

Th17 pathway, 8

toxic shock syndrome, 20

travel, for IBD patients, 19

checklist prior to, 21t

endemic infections and, 19–20
travel, for IBD patients (Continued)
  live vaccines, avoidance of, 20
  malaria, measures for, 20
  pretravel preparation
    alert bracelets, 21
    contact details, 21–2
    journey planning, 21
    medication supply, 21
    travel insurance, 21
    travel letter, 21
  routine immunization in, 19
  travelers' diarrhea, 20
  tuberculosis, measures for,
    20–21
  TREAT registry, 16, 80, 133
  Trichuris suis, 39
  Trichuris trichiura, 39
  tuberculosis, 16, 20
  tumor necrosis factor (TNF), 136
  typhoid fever, 19

  UC SUCCESS trial, 121

  ulcerative colitis (UC)
    5-ASA for, efficacy of, 65–6
    biologics in, 120–22
    colorectal cancer in, 69
    cyclosporine in, 102
    dietary advice in, 231
    helminthic therapy, 39
    laparoscopy for, 179
    mucosal healing in, 204–5
    perioperative use of anti-TNF, and
      postoperative complications in,
        187, 189
    surveillance colonoscopy in, 57–60
    tacrolimus in, 102–3
    ultrasound, 54, 54r
    ultraviolet radiation (UVR), 89
    NMSC, role in, 90
    ursodeoxycholic acid (UDCA), 71, 156
    chemopreventive effect of, 157
    treatment in PSC, 157, 157r
    uveitis, 131
  vaccination, in IBD patients
    before immunosuppressive therapy,
      41
    live virus, 42
    non-live vaccines for, 41
    for risk of vaccine-preventable
      infection, 41
    vaccines for, 42r
    hepatitis B virus, 43
    HPV vaccine, 43
    influenza, 42–3
    measles, mumps, and rubella, 43–4
    meningococcus, 43
    other vaccines, 44
    pneumococcus, 43
    Tdap (Td plus pertussis
      vaccination), 43
    tetanus and diphtheria toxoids (Td),
      43
    varicella vaccine, 43
    zoster vaccine, 43
    valganciclovir, 28
    vancomycin, for CDI treatment, 31
    variations, in healthcare, 243
    varicella vaccine, 43, 135
    Varicella zoster virus (VZV), 17–18
    VDR polymorphisms and development
      of IBD, 210
    viral hepatitis
      effect of treatment for IBD on, 23–4
      and IBD, 23
      treatment of, 25
    vitamin D, 234
      and bone health, 209
      and colorectal adenocarcinoma,
        209–10
      genomic actions of, 210
      hypovitaminosis D in IBD, 207–9
      physiology and metabolism of, 207,
        208f
      and treatment of IBD, 209
      vitamin D-binding protein (DBP), 207
      expression in tumor progression, 210
      polymorphisms and development of
        IBD, 210
    VSL#3, 198
    wheat grass juice, use of, 165
    white light endoscopy (WLE), 59
    Wnt/β-catenin signaling, 70
    wormwood, 165
    xanthine oxidase (XO) inhibitor, 153
    yellow fever vaccine, 20
    zoster vaccine, 43